Payment overview · 2025
General Payments
$164.76
10 reported records · 7 companies
Healthcare provider profile · identity verified
Abir Abdo, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · HAMMOND, LA · NPI 1205071164
Verified facts
What the public records show
CMS Open Payments records show Abir Abdo, M.D. received $164.76 in general payments during 2025 across 10 reported records.
ABBVIE INC. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Linzess, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.58 | 21.6% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $31.74 | 19.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.25 | 18.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.88 | 12.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.08 | 10.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.64 | 10.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.59 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $164.76 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $30.25 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.43 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.08 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.64 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.15 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 52 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 80 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 136 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
80 | 27 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
52 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
136 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
45 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 443 | 123 |
| Pantoprazole Sodium | Pantoprazole Sodium | 434 | 121 |
| Amlodipine Besylate | Amlodipine Besylate | 406 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 114 |
| Trazodone Hcl | Trazodone Hcl | 335 | 90 |
| Metoprolol Succinate | Metoprolol Succinate | 287 | 72 |
| Gabapentin | Gabapentin | 258 | 77 |
| Furosemide | Furosemide | 239 | 67 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 238 | 75 |
| Sertraline Hcl | Sertraline Hcl | 191 | 45 |
| Escitalopram Oxalate | Escitalopram Oxalate | 174 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 37 |
| Losartan Potassium | Losartan Potassium | 158 | 42 |
| Potassium Chloride | Potassium Chloride | 158 | 45 |
| Alprazolam | Alprazolam | 152 | 49 |
| Donepezil Hcl | Donepezil Hcl | 152 | 41 |
| Nifedipine Er | Nifedipine | 151 | 34 |
| Lisinopril | Lisinopril | 145 | 55 |
| Famotidine | Famotidine | 140 | 36 |
| Metformin Hcl | Metformin Hcl | 138 | 42 |
| Allopurinol | Allopurinol | 136 | 29 |
| Mounjaro | Tirzepatide | 136 | 35 |
| Buspirone Hcl | Buspirone Hcl | 135 | 43 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 132 | 32 |
| Memantine Hcl | Memantine Hcl | 129 | 39 |
| Mirtazapine | Mirtazapine | 129 | 39 |
| Omeprazole | Omeprazole | 119 | 43 |
| Ibandronate Sodium | Ibandronate Sodium | 114 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 107 | 22 |
| Eliquis | Apixaban | 106 | 26 |
| Montelukast Sodium | Montelukast Sodium | 105 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 102 | 27 |
| Meloxicam | Meloxicam | 101 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 36 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 99 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 91 | 24 |
| Myrbetriq | Mirabegron | 90 | 20 |
| Quetiapine Fumarate | Quetiapine Fumarate | 90 | 24 |
| Ozempic | Semaglutide | 88 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 28 |
| Linzess | Linaclotide | 80 | 27 |
| Nebivolol Hcl | Nebivolol Hcl | 77 | 16 |
| Tramadol Hcl | Tramadol Hcl | 76 | 27 |
| Tamsulosin Hcl | Tamsulosin Hcl | 75 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 74 | 32 |
| Simvastatin | Simvastatin | 71 | 22 |
| Hydralazine Hcl | Hydralazine Hcl | 68 | 20 |
| Januvia | Sitagliptin Phosphate | 68 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 20 |
| Carvedilol | Carvedilol | 65 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 14 |
| Pregabalin | Pregabalin | 60 | 12 |
| Bupropion Xl | Bupropion Hcl | 59 | 13 |
| Clonidine Hcl | Clonidine Hcl | 57 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 19 |
| Ezetimibe | Ezetimibe | 54 | 19 |
| Lorazepam | Lorazepam | 54 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 52 | 16 |
| Jardiance | Empagliflozin | 52 | 11 |
| Glimepiride | Glimepiride | 51 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 32 |
| Glipizide | Glipizide | 47 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 13 |
| Ondansetron Odt | Ondansetron | 45 | 21 |
| Trulicity | Dulaglutide | 45 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 21 |
| Alendronate Sodium | Alendronate Sodium | 42 | 11 |
| Clonazepam | Clonazepam | 42 | 21 |
| Valsartan | Valsartan | 42 | 12 |
| Temazepam | Temazepam | 41 | suppressed |
| Atenolol | Atenolol | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | 14 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Methylprednisolone | Methylprednisolone | 38 | 36 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | 13 |
| Folic Acid | Folic Acid | 36 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 36 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 36 | 22 |
| Azithromycin | Azithromycin | 35 | 30 |
| Nystatin | Nystatin | 35 | 18 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 33 | 11 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 32 | suppressed |
| Methocarbamol | Methocarbamol | 32 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 31 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Finasteride | Finasteride | 26 | suppressed |
| Fluconazole | Fluconazole | 26 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 26 | 15 |
| Nortriptyline Hcl | Nortriptyline Hcl | 26 | suppressed |
| Sucralfate | Sucralfate | 26 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 24 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 20 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Eszopiclone | Eszopiclone | 22 | suppressed |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 13 |
| Nexletol | Bempedoic Acid | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 18 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Nabumetone | Nabumetone | 18 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 18 | suppressed |
| Topiramate | Topiramate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Calcitriol | Calcitriol | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 16 | suppressed |
| Ibuprofen | Ibuprofen | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 13 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Prednisone | Prednisone | 15 | 12 |
| Primidone | Primidone | 15 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 12 |
| Fosfomycin Tromethamine | Fosfomycin Tromethamine | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Rivastigmine | Rivastigmine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $164.76 · 10 records | ABBVIE INC. | CREON, Cologuard Collection Kit, JARDIANCE, Kerendia, LINZESS, MOUNJARO, NUPLAZID, TRELEGY ELLIPTA, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error